Pioneering a Restorative Approach
Heart valve disease is a serious condition.
In industrialized countries, it affects around 2% of the population and many patients remain undiagnosed.
In these countries, hundreds of thousands of patients undertake heart valve intervention every year. This figure is expected to rise substantially due to aging of the population and better diagnosis of pre-existing heart valve disease.
Biological and mechanical heart valves can be life savers. However, all existing options involve some compromise. Patients with biological valves may endure repeated replacement procedures.
Mechanical valves require long-term medication, with potentially severe side effects.
Xeltis is pioneering a restorative approach in heart valve therapy to overcome the limitations of existing options.
Xeltis’ heart valves enable the patient’s own body to naturally restore a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR).
Xeltis’ history is the culmination of substantial developments in regenerative medicine, supramolecular chemistry and electrospinning.
Research on tissue regeneration, supramolecular polymers and electrospinning join with Frank Baaijens’ group starting research on ‘in situ tissue engineering’, now called ETR.
Xeltis and QTIS merge, abandon tissue engineering to focus on ETR and to develop the RestoreX technology platform.
First patients implanted with Xeltis bioabsorbable blood vessels (pulmonary conduit) and patches.
First patient implanted with Xeltis bioabsorbable pulmonary heart valve in clinical trials, with Thierry Carrel as Principal Investigator.
Xplore-2 trial in US
Xeltis Series C financing round closed
- Small diameter blood vessels enter preclinical trial phasePatient enrolment completed for EFS